Amgen (AMGN) Posts Positive Phase 3 Sjögren's Data As Autoimmune Readout Broadens

• Amgen (NasdaqGS:AMGN) reported positive Phase 3 OASIZ-301 trial results for dazodalibep in Sjögren's disease, showing reduced disease activity.
• At ACR Convergence 2026, the company is sharing long term efficacy and safety data for UPLIZNA in IgG4-related disease.
• Amgen is also presenting new real world evidence on KRYSTEXXA and TAVNEOS in rare and serious autoimmune conditions.
• The dazodalibep OASIZ-301 data in Sjögren's disease is important context, but it should not dominate your view of Amgen. We have also flagged 1 warning sign for Amgen.

For a broader look at how complex disease research is intersecting with new tools in medicine, it is worth exploring 34 healthcare AI stocks.

Amgen is a US biopharma group with a US$240.4 billion market cap that focuses on human therapeutics, so its autoimmune pipeline and real world evidence work at ACR Convergence 2026 feed directly into how the business builds and supports its portfolio of treatments.

Is Amgen's dividend sustainable? Check out what every dividend investor needs to know in our dividend analysis.

How Amgen’s dividend decision ties to autoimmune progress

Amgen’s Narrative assumes the business can keep funding shareholder payouts from a broad mix of cardiometabolic, oncology and rare disease therapies, rather than leaning on a single blockbuster. This fresh autoimmune data and the latest dividend declaration sit right in the middle of that bet on durable, diversified cash generation.

“Analysts expect Amgen to keep building on its cardiometabolic, oncology and rare disease portfolios, with newer growth drivers that already account for most product sales supporting the view that the business can sustain a broad-based revenue and earnings profile...”

See how the full story points towards a $391 fair value for Amgen.

The fourth quarter dividend of US$2.52 per share signals management’s willingness to keep returning cash even as it funds large programs like dazodalibep and UPLIZNA. That lines up with the view that multiple growth drivers, including autoimmune assets, can support both research costs and regular distributions without stretching the payout too far.

Positive Phase 3 readouts in Sjögren's disease and long term autoimmune data may help the dividend case because they speak to the breadth of future treatment options, not just near term milestones. The question is whether this expanding franchise can outpace pricing pressure and biosimilar competition that analysts already flag as key risks for a generous, sustainable dividend.

The same news about autoimmune progress and a reaffirmed payout can look like either disciplined confidence or creeping stretch, depending on which Amgen Narrative you think is playing out.

Add Amgen to your Watchlist and get alerts as these catalysts play out.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com